The tweet was deleted by the author.
But we saved everything 🙂.
Nuvalent wrapped up its participation at the 2026 ASCO Annual Meeting with presentations on its clinical updates. The company presented updates from its ALK+ NSCLC and ROS1+ programs.
Nuvalent reported positive engagements with the oncology community at the event. Team members thanked attendees for joining their oral presentation and visiting their poster.
NUVL is trading well below key moving averages, with the current price of $89.74 under the MA-20 at $101.12, MA-50 at $102.45, and MA-200 at $97.68, signaling pronounced selling pressure across short-, medium-, and long-term trends. The Ichimoku Kijun on D1 sits at $100.21—above the current price—acting as immediate resistance; near-term support emerges at MA-200 ($97.68) and MA-100 ($102.35), while resistance levels cluster at the Kijun ($100.21) and MA-20 ($101.12).
Momentum indicators on D1 remain weak, with MACD signaling "Sell" and ADX at a low 13.28 pointing to a lack of trend strength. RSI and CCI are both in oversold territory, with Stoch RSI also indicating oversold conditions, highlighting elevated short-term downside potential. BBP is deeply negative, confirming that sellers currently dominate intraday flows. In today's session, NUVL is down 1.33%, testing the bottom of its weekly range. Over the past week, the stock has slipped $1.21 (1.20%) from the previous close of $90.95 and is now positioned at the very bottom of its recent price corridor; weekly volatility stands at 6.92%. The week reflects a steady decline from earlier highs without signs of recovery.
Looking ahead, the expected price range for the next week is $87.50–$94.50, anchored proportionally to current volatility and encapsulating recent price action. Based on W1 signals (one Buy among MA-100-w1/MA-200-w1, others indicating Sell/Neutral), the probability of a price increase is very low (less than 20%), making further declines much more likely. The baseline scenario anticipates limited movement within this sideways corridor, with price holding between recent lows and $94.50. A bullish breakout scenario would require a close above $100.21 (Ichimoku Kijun and MA cluster), which currently looks unlikely given both daily and weekly momentum readings. Conversely, should the price break below $87.50, downside risk could accelerate, with the 52-week low at $71.13 as a distant reference but not an immediate target, while the yearly high of $113.02 remains out of reach under current technical conditions.
Previously it was reported that Nuvalent faced continued bearish pressure, with technical indicators signaling limited prospects for a near-term rebound. As the current environment evolves, investors should monitor for any developments that could shift the prevailing downside scenario and watch for emerging catalysts that may impact sentiment.